HB0224 Enrolled

1 AN ACT concerning insurance.

## 2 Be it enacted by the People of the State of Illinois, 3 represented in the General Assembly:

4 Section 5. The Health Carrier External Review Act is 5 amended by changing Sections 10, 20, 25, 30, 35, 40, 55, 65, 6 and 75 and by adding Sections 42 and 80 as follows:

7 (215 ILCS 180/10)

8 Sec. 10. Definitions. For the purposes of this Act:
9 "Adverse determination" means:

(1) a determination by a health carrier or its designee 10 utilization review organization that, based upon the 11 12 information provided, a request for a benefit under the health carrier's health benefit plan upon application of 13 14 any utilization review technique does not meet the health 15 carrier's requirements for medical necessity, 16 appropriateness, health care setting, level of care, or 17 effectiveness or is determined to be experimental or investigational and the requested benefit is therefore 18 19 denied, reduced, or terminated or payment is not provided 20 or made, in whole or in part, for the benefit;

(2) the denial, reduction, or termination of or failure
 to provide or make payment, in whole or in part, for a
 benefit based on a determination by a health carrier or its

HB0224 Enrolled

1 designee utilization review organization that а 2 preexisting condition was present before the effective 3 date of coverage; or (3) a recission of coverage determination, which does 4 5 not include a cancellation or discontinuance of coverage that is attributable to a failure to timely pay required 6 7 premiums or contributions towards the cost of coverage. 8 means a determination by a health carrier or its designee utilization review organization that an admission, 9 10 availability of care, continued stay, or other health care 11 service that is a covered benefit has been reviewed and, 12 based upon the information provided, does not meet the health -carrier's requirements for medical 13 -necessity, 14 appropriateness, health care setting, level of care, or 15 effectiveness, and the requested service or payment for the 16 service is therefore denied, reduced, or terminated. "Authorized representative" means: 17 18 (1) a person to whom a covered person has given express 19 written consent to represent the covered person for 20 purposes of this Law; (2) a person authorized by law to provide substituted 21 22 consent for a covered person; 23 (3) a family member of the covered person or the 24 covered person's treating health care professional when 25 the covered person is unable to provide consent;

26 (4) a health care provider when the covered person's

HB0224 Enrolled - 3 - LRB097 05693 RPM 45756 b

1	health benefit plan requires that a request for a benefit
2	under the plan be initiated by the health care provider; or
3	(5) in the case of an urgent care request, a health
4	care provider with knowledge of the covered person's
5	medical condition.
6	(1) a person to whom a covered person has given express
7	written consent to represent the covered person in an
8	external review, including the covered person's health
9	care provider;
10	(2) a person authorized by law to provide substituted
11	consent for a covered person; or
12	(3) the covered person's health care provider when the
13	covered person is unable to provide consent.
14	"Best evidence" means evidence based on:
15	(1) randomized clinical trials;
16	(2) if randomized clinical trials are not available,
17	then cohort studies or case-control studies;
18	(3) if items (1) and (2) are not available, then
19	case-series; or
20	(4) if items (1), (2), and (3) are not available, then
21	expert opinion.
22	"Case-series" means an evaluation of a series of patients
23	with a particular outcome, without the use of a control group.
24	"Clinical review criteria" means the written screening
25	procedures, decision abstracts, clinical protocols, and
26	practice guidelines used by a health carrier to determine the

HB0224 Enrolled - 4 - LRB097 05693 RPM 45756 b

1 necessity and appropriateness of health care services.

2 "Cohort study" means a prospective evaluation of 2 groups 3 of patients with only one group of patients receiving specific 4 intervention.

5 <u>"Concurrent review" means a review conducted during a</u> 6 patient's stay or course of treatment in a facility, the office 7 <u>of a health care professional, or other inpatient or outpatient</u> 8 health care setting.

9 "Covered benefits" or "benefits" means those health care 10 services to which a covered person is entitled under the terms 11 of a health benefit plan.

12 "Covered person" means a policyholder, subscriber, 13 enrollee, or other individual participating in a health benefit 14 plan.

15 "Director" means the Director of the Department of 16 Insurance.

17 "Emergency medical condition" means a medical condition 18 manifesting itself by acute symptoms of sufficient severity, 19 including, but not limited to, severe pain, such that a prudent 20 layperson who possesses an average knowledge of health and 21 medicine could reasonably expect the absence of immediate 22 medical attention to result in:

(1) placing the health of the individual or, with
respect to a pregnant woman, the health of the woman or her
unborn child, in serious jeopardy;

(2) serious impairment to bodily functions; or

26

HB0224 Enrolled

1

## - 5 - LRB097 05693 RPM 45756 b

(3) serious dysfunction of any bodily organ or part.

2 "Emergency services" means health care items and services 3 furnished or required to evaluate and treat an emergency 4 medical condition.

5 "Evidence-based standard" means the conscientious, 6 explicit, and judicious use of the current best evidence based 7 on an overall systematic review of the research in making 8 decisions about the care of individual patients.

9 "Expert opinion" means a belief or an interpretation by 10 specialists with experience in a specific area about the 11 scientific evidence pertaining to a particular service, 12 intervention, or therapy.

13 "Facility" means an institution providing health care 14 services or a health care setting.

15 "Final adverse determination" means an adverse 16 determination involving a covered benefit that has been upheld 17 by a health carrier, or its designee utilization review 18 organization, at the completion of the health carrier's 19 internal grievance process procedures as set forth by the 20 Managed Care Reform and Patient Rights Act.

21 "Health benefit plan" means a policy, contract, 22 certificate, plan, or agreement offered or issued by a health 23 carrier to provide, deliver, arrange for, pay for, or reimburse 24 any of the costs of health care services.

25 "Health care provider" or "provider" means a physician, 26 hospital facility, or other health care practitioner licensed, HB0224 Enrolled - 6 - LRB097 05693 RPM 45756 b

1 accredited, or certified to perform specified health care 2 services consistent with State law, responsible for 3 recommending health care services on behalf of a covered 4 person.

5 "Health care services" means services for the diagnosis,
6 prevention, treatment, cure, or relief of a health condition,
7 illness, injury, or disease.

8 "Health carrier" means an entity subject to the insurance 9 laws and regulations of this State, or subject to the 10 jurisdiction of the Director, that contracts or offers to 11 contract to provide, deliver, arrange for, pay for, or 12 reimburse any of the costs of health care services, including a 13 sickness and accident insurance company, a health maintenance organization, or any other entity providing a plan of health 14 15 insurance, health benefits, or health care services. "Health 16 carrier" also means Limited Health Service Organizations 17 (LHSO) and Voluntary Health Service Plans.

18 "Health information" means information or data, whether 19 oral or recorded in any form or medium, and personal facts or 20 information about events or relationships that relate to:

(1) the past, present, or future physical, mental, or
behavioral health or condition of an individual or a member
of the individual's family;

24 (2) the provision of health care services to an25 individual; or

26

(3) payment for the provision of health care services

HB0224 Enrolled - 7 - LRB097 05693 RPM 45756 b

1 to an individual.

2 "Independent review organization" means an entity that
3 conducts independent external reviews of adverse
4 determinations and final adverse determinations.

5 "Medical or scientific evidence" means evidence found in 6 the following sources:

7 (1) peer-reviewed scientific studies published in or 8 accepted for publication by medical journals that meet 9 nationally recognized requirements for scientific 10 manuscripts and that submit most of their published 11 articles for review by experts who are not part of the 12 editorial staff;

13 medical literature, (2)peer-reviewed including 14 literature relating to therapies reviewed and approved by a 15 qualified institutional review board, biomedical 16 compendia, and other medical literature that meet the 17 criteria of the National Institutes of Health's Library of Medicine for indexing in Index Medicus (Medline) and 18 Elsevier Science Ltd. for indexing in Excerpta Medicus 19 20 (EMBASE);

(3) medical journals recognized by the Secretary of Health and Human Services under Section 1861(t)(2) of the federal Social Security Act;

24

(4) the following standard reference compendia:

(a) The American Hospital Formulary Service-Drug
 Information;

HB0224 Enrolled - 8 - LRB097 05693 RPM 45756 b (b) Drug Facts and Comparisons; 1 The American Dental Association Accepted 2 (C)3 Dental Therapeutics; and (d) The United States Pharmacopoeia-Drug 4 5 Information: (5) findings, studies, or research conducted by or 6 7 under the auspices of federal government agencies and 8 nationally recognized federal research institutes, 9 including: 10 (a) the federal Agency for Healthcare Research and 11 Quality; 12 (b) the National Institutes of Health; 13 (c) the National Cancer Institute; (d) the National Academy of Sciences; 14 15 (e) the Centers for Medicare & Medicaid Services: 16 (f) the federal Food and Drug Administration; and 17 (q) any national board recognized by the National Institutes of Health for the purpose of evaluating the 18 medical value of health care services; or 19 20 (6) any other medical or scientific evidence that is 21 comparable to the sources listed in items (1) through (5). 22 "Person" means an individual, a corporation, a 23 partnership, an association, a joint venture, a joint stock 24 company, a trust, an unincorporated organization, any similar 25 entity, or any combination of the foregoing. 26 "Prospective review" means a review conducted prior to an

HB0224 Enrolled - 9 - LRB097 05693 RPM 45756 b

1 admission or the provision of a health care service or a course 2 of treatment in accordance with a health carrier's requirement 3 that the health care service or course of treatment, in whole 4 or in part, be approved prior to its provision.

5 "Protected health information" means health information 6 (i) that identifies an individual who is the subject of the 7 information; or (ii) with respect to which there is a 8 reasonable basis to believe that the information could be used 9 to identify an individual.

10 <u>"Randomized clinical trial" means a controlled prospective</u> 11 <u>study of patients that have been randomized into an</u> 12 <u>experimental group and a control group at the beginning of the</u> 13 <u>study with only the experimental group of patients receiving a</u> 14 <u>specific intervention, which includes study of the groups for</u> 15 variables and anticipated outcomes over time.

16 "Retrospective review" means any review of a request for a 17 benefit that is not a concurrent or prospective review request. "Retrospective review" does not include the review of a claim 18 19 that is limited to veracity of documentation or accuracy of 20 coding. means a review of medical necessity conducted after 21 services have been provided to a patient, but does not include the review of a claim that is limited to an evaluation of 22 23 reimbursement levels, veracity of documentation, accuracy 24 coding, or adjudication for payment.

25 "Utilization review" has the meaning provided by the26 Managed Care Reform and Patient Rights Act.

HB0224 Enrolled - 10 - LRB097 05693 RPM 45756 b

"Utilization review organization" means a utilization
 review program as defined in the Managed Care Reform and
 Patient Rights Act.

4 (Source: P.A. 96-857, eff. 7-1-10.)

5 (215 ILCS 180/20)

6 Sec. 20. Notice of right to external review.

7 (a) At the same time the health carrier sends written 8 notice of a covered person's right to appeal a coverage 9 decision upon an adverse determination or a final adverse 10 determination as provided by the Managed Care Reform and 11 Patient Rights Act, a health carrier shall notify a covered 12 person, the covered person's authorized representative, if any, and a covered person's health care provider in writing of 13 14 the covered person's right to request an external review as 15 provided by this Act. The written notice required shall include 16 the following, or substantially equivalent, language: "We have denied your request for the provision of or payment for a 17 health care service or course of treatment. You have the right 18 to have our decision reviewed by an independent review 19 organization not associated with us if our decision involved 20 21 making a judgment as to the medical necessity, appropriateness, 22 health care setting, level of care, or effectiveness of the 23 health care service or treatment you requested by submitting a 24 written request for an external review to the Department of Insurance, Office of Consumer Health Information, 320 West 25

HB0224 Enrolled - 11 - LRB097 05693 RPM 45756 b

Mashington Street, 4th Floor, Springfield, Illinois, 62767."
Us. Upon receipt of your request an independent review
organization registered with the Department of Insurance will
be assigned to review our decision.

5 <u>(a-5) The Department may prescribe the form and content of</u>
6 the notice required under this Section.

7 (b) This subsection (b) shall apply to an expedited review 8 prior to a final adverse determination. In addition to the 9 notice required in subsection (a), <u>for</u> the health carrier shall 10 <u>include</u> a notice related to an adverse determination, <u>the</u> 11 <u>health carrier shall include</u> a statement informing the covered 12 person <u>of</u> all of the following:

13 (1) If the covered person has a medical condition where 14 the timeframe for completion of (A) an expedited internal 15 review of an appeal a grievance involving an adverse determination, (B) a final adverse determination as set 16 17 forth in the Managed Care Reform and Patient Rights Act, or (C) a standard external review as established in this Act, 18 19 would seriously jeopardize the life or health of the covered person or would jeopardize the covered person's 20 ability to regain maximum function, then the covered person 21 22 or the covered person's authorized representative may file 23 a request for an expedited external review.

24 (2) <u>The covered person or the covered person's</u>
 25 <u>authorized representative may file an appeal under the</u>
 26 <u>health carrier's internal appeal process, but if the health</u>

HB0224 Enrolled - 12 - LRB097 05693 RPM 45756 b

1	carrier has not issued a written decision to the covered
2	person or the covered person's authorized representative
3	30 days following the date the covered person or the
4	covered person's authorized representative files an appeal
5	of an adverse determination that involves a concurrent or
6	prospective review request or 60 days following the date
7	the covered person or the covered person's authorized
8	representative files an appeal of an adverse determination
9	that involves a retrospective review request with the
10	health carrier and the covered person or the covered
11	person's authorized representative has not requested or
12	agreed to a delay, then the covered person or the covered
13	person's authorized representative may file a request for
14	external review and shall be considered to have exhausted
15	the health carrier's internal appeal process for purposes
16	of this Act. The covered person or the covered person's
17	authorized representative may file a request for an
18	expedited external review at the same time the covered
19	person or the covered person's authorized representative
20	files a request for an expedited internal appeal involving
21	an adverse determination as set forth in the Managed Care
22	Reform and Patient Rights Act if the adverse determination
23	involves a denial of coverage based on a determination that
24	the recommended or requested health care service or
25	treatment is experimental or investigational and the
26	covered person's health care provider certifies in writing

HB0224 Enrolled

4

5

1 that the recommended or requested health care service 2 treatment that is the subject of the adverse determination be significantly less effective if not promptly 3 initiated. The independent review organization assigned conduct the expedited external review will determine 6 whether the covered person shall be required to complete the expedited review of the grievance prior 7 8 the expedited external review.

9 (3) If the covered person or the covered person's 10 authorized representative filed a request for an expedited 11 internal review of an adverse determination and has not 12 received a decision on such request from the health carrier 13 within 48 hours, except to the extent the covered person or 14 the covered person's authorized representative requested or agreed to a delay, then the covered person or the 15 16 covered person's authorized representative may file a 17 request for external review and shall be considered to have exhausted the health carrier's internal appeal process for 18 19 the purposes of this Act.

20 (4) (3) If an adverse determination concerns a denial of coverage based on a determination that the recommended 21 22 requested health care service or treatment is or 23 experimental or investigational and the covered person's 24 health care provider certifies in writing that the 25 recommended or requested health care service or treatment 26 that is the subject of the request would be significantly HB0224 Enrolled - 14 - LRB097 05693 RPM 45756 b

less effective if not promptly initiated, then the covered 1 2 person or the covered person's authorized representative 3 may request an expedited external review at the same time the covered person or the covered person's authorized 4 5 representative files a request for an expedited internal 6 appeal involving an adverse determination. The independent review organization assigned to conduct the expedited 7 8 external review shall determine whether the covered person 9 is required to complete the expedited review of the appeal prior to conducting the expedited external review. 10

(c) This subsection (c) shall apply to an expedited review upon final adverse determination. In addition to the notice required in subsection (a), <u>for</u> the health carrier shall include a notice related to a final adverse determination, <u>the</u> <u>health carrier shall include</u> a statement informing the covered person <u>of</u> all of the following:

(1) if the covered person has a medical condition where the timeframe for completion of a standard external review would seriously jeopardize the life or health of the covered person or would jeopardize the covered person's ability to regain maximum function, then the covered person or the covered person's authorized representative may file a request for an expedited external review; or

(2) if a final adverse determination concerns an
 admission, availability of care, continued stay, or health
 care service for which the covered person received

HB0224 Enrolled - 15 - LRB097 05693 RPM 45756 b

emergency services, but has not been discharged from a facility, then the covered person, or the covered person's authorized representative, may request an expedited external review; or

5 (3) if a final adverse determination concerns a denial 6 of coverage based on a determination that the recommended 7 requested health care service or treatment or is 8 experimental or investigational, and the covered person's 9 health care provider certifies in writing that the 10 recommended or requested health care service or treatment 11 that is the subject of the request would be significantly 12 less effective if not promptly initiated, then the covered 13 person or the covered person's authorized representative 14 may request an expedited external review.

15 (d) In addition to the information to be provided pursuant 16 to subsections (a), (b), and (c) of this Section, the health 17 carrier shall include a copy of the description of both the required standard and expedited external review procedures. 18 19 The description shall highlight the external review procedures 20 that give the covered person or the covered person's authorized 21 representative the opportunity to submit additional 22 information, including any forms used to process an external 23 review.

(e) As part of any forms provided under subsection (d) of
 this Section, the health carrier shall include an authorization
 form, or other document approved by the Director, by which the

HB0224 Enrolled - 16 - LRB097 05693 RPM 45756 b

1 covered person, for purposes of conducting an external review
2 under this Act, authorizes the health carrier and the covered
3 person's treating health care provider to disclose protected
4 health information, including medical records, concerning the
5 covered person that is pertinent to the external review, as
6 provided in the Illinois Insurance Code.

7 (Source: P.A. 96-857, eff. 7-1-10.)

8 (215 ILCS 180/25)

9 Sec. 25. Request for external review. A covered person or 10 the covered person's authorized representative may make a 11 request for a standard external or expedited external review of 12 an adverse determination or final adverse determination. 13 Except as set forth in Sections 40 and 42 of this Act, all requests for external review Requests under this Section shall 14 15 be made in writing to the Director directly to the health 16 carrier that made the adverse or final adverse determination. All requests for external review shall be in writing except for 17 18 requests for expedited external reviews which may me made orally. Health carriers must provide covered persons with forms 19 to request external reviews. 20

21 (Source: P.A. 96-857, eff. 7-1-10.)

22 (215 ILCS 180/30)

23 Sec. 30. Exhaustion of internal <u>appeal</u> grievance process.

24 (a) Except as provided in subsection (b) of this Section

HB0224 Enrolled - 17 - LRB097 05693 RPM 45756 b

20, a request for an external review shall not be made until
 the covered person has exhausted the health carrier's internal
 <u>appeal</u> grievance process as set forth in the Managed Care
 <u>Reform and Patient Rights Act</u>.

5 <u>(b)</u> A covered person shall also be considered to have 6 exhausted the health carrier's internal <u>appeal</u> grievance 7 process for purposes of this Section if:

8 the covered person or the covered person's (1)9 authorized representative has filed an appeal under the 10 health carrier's internal appeal process a request for an 11 internal review of an adverse determination pursuant to the 12 Managed Care Reform and Patient Rights Act and has not 13 received a written decision on the appeal 30 days following 14 the date the covered person or the covered person's authorized representative files an appeal of an adverse 15 16 determination that involves a concurrent or prospective 17 review request or 60 days following the date the covered person or the covered person's authorized representative 18 19 files an appeal of an adverse determination that involves a 20 retrospective review request request from the health 21 carrier within 15 days after receipt of the required 22 information but not more than 30 days after the request was 23 filed by the covered person or the covered person's 24 authorized representative, except to the extent the 25 covered person or the covered person's authorized 26 representative requested or agreed to a delay; however, a

1 person or the covered person's authorized <del>covered</del> 2 representative may not make a request for an external 3 reviewof an adverse determination involving -review--determination until 4 retrospectivethe 5 has exhausted the health 6 grievance process;

7 the covered person or the covered person's (2) 8 authorized representative filed a request for an expedited 9 internal review of an adverse determination pursuant to the 10 Managed Care Reform and Patient Rights Act and has not 11 received a decision on such request from the health carrier 12 within 48 hours, except to the extent the covered person or 13 the covered person's authorized representative requested 14 or agreed to a delay; or

15 (3) the health carrier agrees to waive the exhaustion 16 requirement<u>;</u>.

17 (4) the covered person has a medical condition in which the timeframe for completion of (A) an expedited internal 18 19 review of an appeal involving an adverse determination, (B) a final adverse determination, or (C) a standard external 20 21 review as established in this Act would seriously 22 jeopardize the life or health of the covered person or 23 would jeopardize the covered person's ability to regain 24 maximum function;

25(5) an adverse determination concerns a denial of26coverage based on a determination that the recommended or

HB0224 Enrolled - 19 - LRB097 05693 RPM 45756 b

1	requested health care service or treatment is experimental
2	or investigational and the covered person's health care
3	provider certifies in writing that the recommended or
4	requested health care service or treatment that is the
5	subject of the request would be significantly less
6	effective if not promptly initiated; in such cases, the
7	covered person or the covered person's authorized
8	representative may request an expedited external review at
9	the same time the covered person or the covered person's
10	authorized representative files a request for an expedited
11	internal appeal involving an adverse determination; the
12	independent review organization assigned to conduct the
13	expedited external review shall determine whether the
14	covered person is required to complete the expedited review
15	of the appeal prior to conducting the expedited external
16	review; or
17	(6) the health carrier has failed to comply with

18 <u>applicable State and federal law governing internal claims</u>
 19 <u>and appeals procedures.</u>

20 (Source: P.A. 96-857, eff. 7-1-10.)

21 (215 ILCS 180/35)

22 Sec. 35. Standard external review.

(a) Within 4 months after the date of receipt of a notice
of an adverse determination or final adverse determination, a
covered person or the covered person's authorized

HB0224 Enrolled - 20 - LRB097 05693 RPM 45756 b

representative may file a request for an external review with 1 2 the Director. Within one business day after the date of receipt of a request for external review, the Director shall send a 3 copy of the request to the health carrier. 4

5 (b) Within 5 business days following the date of receipt of the external review request, the health carrier shall complete 6 7 a preliminary review of the request to determine whether:

8

(1) the individual is or was a covered person in the 9 health benefit plan at the time the health care service was 10 requested or at the time the health care service was 11 provided;

12 (2) the health care service that is the subject of the 13 adverse determination or the final adverse determination 14 is a covered service under the covered person's health 15 benefit plan, but the health carrier has determined that 16 the health care service is not covered because it does not 17 meet the health carrier's requirements for medical 18 necessity, appropriateness, health care setting, of 19 care, or effectiveness;

the covered person has exhausted the health 20 (3) 21 carrier's internal appeal grievance process unless the 22 covered person is not required to exhaust the health 23 carrier's internal appeal process pursuant to as set forth 24 in this Act:

25 (4) (blank); and for \_\_\_\_ appeals -relating 26 determination based on treatment being experimental

1	investigational, the requested health care service or
2	treatment that is the subject of the adverse determination
3	or final adverse determination is a covered benefit under
4	the covered person's health benefit plan except for the
5	health carrier's determination that the service or
6	treatment is experimental or investigational for a
7	particular medical condition and is not explicitly listed
8	as an excluded benefit under the covered person's health
9	benefit plan with the health carrier and that the covered
10	person's health care provider, who ordered or provided the
11	services in question and who is licensed under the Medical
12	Practice Act of 1987, has certified that one of the
13	following situations is applicable:
14	(A) standard health care services or treatments
15	have not been effective in improving the condition of
16	the covered person;
17	(B) standard health care services or treatments
18	are not medically appropriate for the covered person;
19	(C) there is no available standard health care

19(C) there is no available standard health care20service or treatment covered by the health carrier that21is more beneficial than the recommended or requested22health care service or treatment;

(D) the health care service or treatment is likely
 to be more beneficial to the covered person, in the
 health care provider's opinion, than any available
 standard health care services or treatments; or

HB0224 Enrolled

1(E) that scientifically valid studies using2accepted protocols demonstrate that the health care3service or treatment requested is likely to be more4beneficial to the covered person than any available5standard health care services or treatments; and

6 (5) the covered person has provided all the information 7 and forms required to process an external review, as 8 specified in this Act.

9 (c) Within one business day after completion of the 10 preliminary review, the health carrier shall notify the 11 <u>Director and</u> covered person and, if applicable, the covered 12 person's authorized representative in writing whether the 13 request is complete and eligible for external review. If the 14 request:

15 (1) is not complete, the health carrier shall inform 16 the <u>Director and</u> covered person and, if applicable, the 17 covered person's authorized representative in writing and 18 include in the notice what information or materials are 19 required by this Act to make the request complete; or

(2) is not eligible for external review, the health
carrier shall inform the <u>Director and</u> covered person and,
if applicable, the covered person's authorized
representative in writing and include in the notice the
reasons for its ineligibility.

25The Department may specify the form for the health26carrier's notice of initial determination under this

HB0224 Enrolled - 23 - LRB097 05693 RPM 45756 b

## 1 <u>subsection (c) and any supporting information to be included in</u> 2 the notice.

3 The notice of initial determination of ineligibility shall 4 include a statement informing the covered person and, if 5 applicable, the covered person's authorized representative 6 that a health carrier's initial determination that the external 7 review request is ineligible for review may be appealed to the 8 Director by filing a complaint with the Director.

9 Notwithstanding a health carrier's initial determination 10 that the request is ineligible for external review, the 11 Director may determine that a request is eligible for external 12 review and require that it be referred for external review. In 13 making such determination, the Director's decision shall be in accordance with the terms of the covered person's health 14 benefit plan, unless such terms are inconsistent with 15 16 applicable law, and shall be subject to all applicable 17 provisions of this Act.

(d) Whenever <u>the Director receives notice that</u> a request is
eligible for external review <u>following the preliminary review</u>
<u>conducted pursuant to this Section</u> the health carrier shall,
within <u>one</u> <del>5</del> business <u>day after the date of receipt of the</u>
<u>notice, the Director shall</u> <del>days</del>:

(1) assign an independent review organization from the
 list of approved independent review organizations compiled
 and maintained by the Director <u>pursuant to this Act and</u>
 <u>notify the health carrier of the name of the assigned</u>

HB0224 Enrolled - 24 - LRB097 05693 RPM 45756 b

1

## independent review organization; and

2 (2) notify in writing the covered person and, if applicable, the covered person's authorized representative 3 of the request's eligibility and acceptance for external 4 5 review and the name of the independent review organization. The Director health carrier shall include in the notice 6 provided to the covered person and, if applicable, the covered 7 8 person's authorized representative a statement that the 9 covered the covered person's authorized person or 10 representative may, within 5 business days following the date 11 of receipt of the notice provided pursuant to item (2) of this 12 subsection (d), submit in writing to the assigned independent 13 organization additional information review that the independent review organization shall consider when conducting 14 15 the external review. The independent review organization is not 16 required to, but may, accept and consider additional 17 information submitted after 5 business days.

The assignment by the Director of an approved 18 (e) 19 independent review organization to conduct an external review 20 in accordance with this Section shall be done on a random basis among those independent review organizations approved by the 21 22 Director pursuant to this Act. The assignment of an approved 23 independent review organization to conduct an external in accordance with this Section shall be made from those 24 25 approved independent review organizations qualified to conduct 26 external review as required by Sections 50 and 55 of this Act.

HB0224 Enrolled - 25 - LRB097 05693 RPM 45756 b

Within Upon assignment of an independent review 1 (f) 2 organization, the health carrier or its designee utilization 3 review organization shall, within 5 business days after the date of receipt of the notice provided pursuant to item (1) of 4 5 subsection (d) of this Section, the health carrier or its designee utilization review organization shall provide to the 6 7 assigned independent review organization the documents and any 8 information considered in making the adverse determination or 9 final adverse determination; in such cases, the following 10 provisions shall apply:

11 (1) Except as provided in item (2) of this subsection 12 (f), failure by the health carrier or its utilization 13 organization provide review to the documents and information within the specified time frame shall not delay 14 15 the conduct of the external review.

16 (2) If the health carrier or its utilization review 17 organization fails to provide the documents and information within the specified time frame, the assigned 18 independent review organization may terminate the external 19 20 review and make a decision to reverse the adverse determination or final adverse determination. 21

(3) Within one business day after making the decision
to terminate the external review and make a decision to
reverse the adverse determination or final adverse
determination under item (2) of this subsection (f), the
independent review organization shall notify the <u>Director</u>,

HB0224 Enrolled - 26 - LRB097 05693 RPM 45756 b

<u>the</u> health carrier, the covered person and, if applicable,
 the covered person's authorized representative, of its
 decision to reverse the adverse determination.

(q) Upon receipt of the information from the health carrier 4 5 its utilization review organization, the assigned or 6 independent review organization shall review all of the 7 information and documents and any other information submitted 8 in writing to the independent review organization by the 9 the covered person's authorized covered person and 10 representative.

(h) Upon receipt of any information submitted by the covered person or the covered person's authorized representative, the independent review organization shall forward the information to the health carrier within 1 business day.

16 (1) Upon receipt of the information, if any, the health
17 carrier may reconsider its adverse determination or final
18 adverse determination that is the subject of the external
19 review.

(2) Reconsideration by the health carrier of its
 adverse determination or final adverse determination shall
 not delay or terminate the external review.

(3) The external review may only be terminated if the
 health carrier decides, upon completion of its
 reconsideration, to reverse its adverse determination or
 final adverse determination and provide coverage or

payment for the health care service that is the subject of
 the adverse determination or final adverse determination.
 In such cases, the following provisions shall apply:

Within one business day after making the 4 (A) 5 decision to reverse its adverse determination or final adverse determination, the health carrier shall notify 6 7 the <u>Director, the</u> covered person and, if applicable, 8 the covered person's authorized representative, and 9 assigned independent review organization the in 10 writing of its decision.

(B) Upon notice from the health carrier that the health carrier has made a decision to reverse its adverse determination or final adverse determination, the assigned independent review organization shall terminate the external review.

16 (i) In addition to the documents and information provided by the health carrier or its utilization review organization 17 18 and the covered person and the covered person's authorized 19 representative, if any, the independent review organization, 20 to the extent the information or documents are available and 21 the independent review organization considers them 22 appropriate, shall consider the following in reaching a 23 decision:

(1) the covered person's pertinent medical records;
(2) the covered person's health care provider's
recommendation;

HB0224 Enrolled

26

1 (3) consulting reports from appropriate health care 2 providers and other documents submitted by the health 3 carrier <u>or its designee utilization review organization</u>, 4 the covered person, the covered person's authorized 5 representative, or the covered person's treating provider;

6 (4) the terms of coverage under the covered person's 7 health benefit plan with the health carrier to ensure that 8 the independent review organization's decision is not 9 contrary to the terms of coverage under the covered 10 person's health benefit plan with the health carrier<u>\_</u> 11 <u>unless the terms are inconsistent with applicable law;</u>

12 (5) the most appropriate practice guidelines, which 13 shall include applicable evidence-based standards and may 14 include any other practice guidelines developed by the 15 federal government, national or professional medical 16 societies, boards, and associations;

17 (6) any applicable clinical review criteria developed
18 and used by the health carrier or its designee utilization
19 review organization; and

20 (7)the opinion of the independent review 21 organization's clinical reviewer or reviewers after 22 considering items (1) through (6) of this subsection (i) to 23 the extent the information or documents are available and 24 the clinical reviewer or reviewers considers the 25 information or documents appropriate; and

(8) <u>(blank).</u> <del>for a denial of coverage based on a</del>

1determination that the health care service or treatment2recommended or requested is experimental or3investigational, whether and to what extent:

4 (A) the recommended or requested health care
5 service or treatment has been approved by the federal
6 Food and Drug Administration, if applicable, for the
7 condition;

medical or scientific evidence 8 <del>(B)</del> 0r evidence based standards demonstrate that the expected 9 10 benefits of the recommended or requested health care 11 service or treatment is more likely than not to be 12 beneficial to the covered person than any available standard health care service or treatment and 13 the adverse risks of the recommended or requested health 14 15 care service or treatment would not be substantially increased over those of available standard health care 16 17 services or treatments; or

18 (C) the terms of coverage under the covered 19 person's health benefit plan with the health carrier to 20 ensure that the health care service or treatment that 21 is the subject of the opinion is experimental or 22 investigational would otherwise be covered under the 23 terms of coverage of the covered person's health 24 benefit plan with the health carrier.

(j) Within 5 days after the date of receipt of all
 necessary information, <u>but in no event more than 45 days after</u>

HB0224 Enrolled - 30 - LRB097 05693 RPM 45756 b

1 the date of receipt of the request for an external review, the assigned independent review organization shall provide written 2 3 notice of its decision to uphold or reverse the adverse determination or the final adverse determination to the 4 5 Director, the health carrier, the covered person, and, if 6 applicable, the covered person's authorized representative. In 7 reaching a decision, the assigned independent review 8 organization is not bound by any claim determinations reached 9 prior to the submission of information to the independent 10 review organization. In such cases, the following provisions 11 shall apply:

12

13

24

(1) The independent review organization shall include in the notice:

14 (A) a general description of the reason for the15 request for external review;

(B) the date the independent review organization
 received the assignment from the <u>Director</u> health
 carrier to conduct the external review;

19 (C) the time period during which the external20 review was conducted;

(D) references to the evidence or documentation,
including the evidence-based standards, considered in
reaching its decision;

(E) the date of its decision; and

(F) the principal reason or reasons for itsdecision, including what applicable, if any,

HB0224 Enrolled - 31 - LRB097 05693 RPM 45756 b evidence-based standards that were a basis for its 1 decision; and. 2 3 (G) the rationale for its decision. (Blank). For reviews of experimental or 4 (2) 5 investigational treatments, the notice shall include the following information: 6 7 (A) a description of the covered person's medical 8 condition; 9 (B) a description of the indicators relevant to whether there is sufficient evidence to demonstrate 10 11 that the recommended or requested health care service 12 or treatment is more likely than not to be more 13 beneficial to the covered person than any available standard health care services or treatments and the 14 adverse risks of the recommended or requested health 15 care service or treatment would not be substantially 16 17 increased over those of available standard health care 18 services or treatments; 19 (C) a description and analysis of any medical or scientific evidence considered in reaching the 20 21 opinion; 22 (D) a description and analysis of any 23 evidence-based standards; (E) whether the recommended or requested health 24 25 care service or treatment has been approved by the 26 federal Food and Drug Administration, for the 1 condition;

(F) whether medical or scientific evidence or 2 evidence-based standards demonstrate that the expected 3 benefits of the recommended or requested health care 4 5 service or treatment is more likely than not to be more 6 beneficial to the covered person than any available 7 standard health care service or treatment and the adverse risks of the recommended or requested health 8 care service or treatment would not be substantially 9 10 increased over those of available standard health care 11 services or treatments; and 12 (C) the written opinion of the clinical reviewer, 13 including the reviewer's recommendation as to whet

14the recommended or requested health care service or15treatment should be covered and the rationale for the16reviewer's recommendation.

(3) <u>(Blank)</u>. In reaching a decision, the assigned
 independent review organization is not bound by any
 decisions or conclusions reached during the health
 carrier's utilization review process or the health
 carrier's internal grievance or appeals process.

(4) Upon receipt of a notice of a decision reversing
the adverse determination or final adverse determination,
the health carrier immediately shall approve the coverage
that was the subject of the adverse determination or final
adverse determination.

HB0224 Enrolled - 33 - LRB097 05693 RPM 45756 b (Source: P.A. 96-857, eff. 7-1-10; 96-967, eff. 1-1-11.) 1 (215 ILCS 180/40) 2 3 Sec. 40. Expedited external review. 4 (a) A covered person or a covered person's authorized 5 representative may file a request for an expedited external 6 review with the <u>Director</u> health carrier either orally or in 7 writing: 8 (1) immediately after the date of receipt of a notice 9 prior to a final adverse determination as provided by 10 subsection (b) of Section 20 of this Act; 11 (2) immediately after the date of receipt of a notice 12 final adverse determination as upon a provided by subsection (c) of Section 20 of this Act; or 13 14 (3) if a health carrier fails to provide a decision on 15 request for an expedited internal appeal within 48 hours as 16 provided by item (2) of Section 30 of this Act. (b) Upon receipt of a request for an expedited external 17 18 review, the Director shall immediately send a copy of the request to the health carrier. Immediately upon receipt of the 19 20 request for an expedited external review as provided under 21 subsections (b) and (c) of Section 20, the health carrier shall 22 determine whether the request meets the reviewability requirements set forth in items (1), (2), and (4) of subsection 23 24 (b) of Section 35. In such cases, the following provisions 25 shall apply:

HB0224 Enrolled

26

1 (1) The health carrier shall immediately notify the 2 <u>Director, the</u> covered person<u>,</u> and, if applicable, the 3 covered person's authorized representative of its 4 eligibility determination.

5 (2) The notice of initial determination shall include a 6 statement informing the covered person and, if applicable, 7 the covered person's authorized representative that a 8 health carrier's initial determination that an external 9 review request is ineligible for review may be appealed to 10 the Director.

11 (3) The Director may determine that a request is 12 eligible for expedited external review notwithstanding a 13 health carrier's initial determination that the request is 14 ineligible and require that it be referred for external 15 review.

(4) In making a determination under item (3) of this
subsection (b), the Director's decision shall be made in
accordance with the terms of the covered person's health
benefit plan, unless such terms are inconsistent with
applicable law, and shall be subject to all applicable
provisions of this Act.

22 (5) The Director may specify the form for the health 23 carrier's notice of initial determination under this 24 subsection (b) and any supporting information to be 25 included in the notice.

(c) Upon receipt of the notice that the request meets the

HB0224 Enrolled - 35 - LRB097 05693 RPM 45756 b

reviewability requirements, determining that a request meets 1 2 the requirements of subsections (b) and (c) of Section  $20_r$  the 3 <del>health carrier</del> shall immediately Director assign an independent review organization from the list of approved 4 5 independent review organizations compiled and maintained by the Director to conduct the expedited review. In such cases, 6 7 the following provisions shall apply:

8 (1) The assignment of an approved independent review 9 organization to conduct an external review in accordance 10 with this Section shall be made from those approved 11 independent review organizations qualified to conduct 12 external review as required by Sections 50 and 55 of this 13 Act.

14 (2) The Director shall immediately notify the health carrier of the name of the assigned independent review 15 16 organization. Immediately upon receipt from the Director 17 of the name of the independent review organization assigned to conduct the external review assigning an independent 18 19 review organization to perform an expedited external 20 review, but in no case more than 24 hours after receiving 21 such notice assigning the independent review organization, 22 the health carrier or its designee utilization review 23 organization shall provide or transmit all necessary documents and information considered in making the adverse 24 25 determination or final adverse determination to the 26 assigned independent review organization electronically or

HB0224 Enrolled - 36 - LRB097 05693 RPM 45756 b

by telephone or facsimile or any other available
 expeditious method.

(3) If the health carrier or its utilization review 3 organization fails to provide the documents 4 and 5 information within the specified timeframe, the assigned independent review organization may terminate the external 6 review and make a decision to reverse 7 the adverse determination or final adverse determination. 8

9 (4) Within one business day after making the decision to terminate the external review and make a decision to 10 11 reverse the adverse determination or final adverse 12 determination under item (3) of this subsection (c), the 13 independent review organization shall notify the Director, 14 the health carrier, the covered person, and, if applicable, 15 the covered person's authorized representative of its 16 decision to reverse the adverse determination or final 17 adverse determination.

(d) In addition to the documents and information provided 18 by the health carrier or its utilization review organization 19 20 and any documents and information provided by the covered 21 person and the covered person's authorized representative, the 22 independent review organization, to the extent the information 23 or documents are available and the independent review 24 organization considers them appropriate, shall consider 25 information as required by subsection (i) of Section 35 of this 26 Act in reaching a decision.

HB0224 Enrolled - 37 - LRB097 05693 RPM 45756 b

1 (e) As expeditiously as the covered person's medical 2 condition or circumstances requires, but in no event more than 3 <u>72 hours after the date of receipt of the request for an</u> 4 <u>expedited external review</u> <del>2 business days after the receipt of</del> 5 <del>all pertinent information</del>, the assigned independent review 6 organization shall:

7 (1) make a decision to uphold or reverse the final
8 adverse determination; and

9 (2) notify the <u>Director, the</u> health carrier, the 10 covered person, the covered person's health care provider, 11 and, if applicable, the covered person's authorized 12 representative, of the decision.

(f) In reaching a decision, the assigned independent review organization is not bound by any decisions or conclusions reached during the health carrier's utilization review process or the health carrier's internal <u>appeal</u> grievance process <del>as</del> <del>set forth in the Managed Care Reform and Patient Rights Act</del>.

(g) Upon receipt of notice of a decision reversing the adverse determination or final adverse determination, the health carrier shall immediately approve the coverage that was the subject of the <u>adverse determination or</u> final adverse determination.

(h) <u>If the notice provided pursuant to subsection (e) of</u>
this Section was not in writing, then within Within 48 hours
after the date of providing <u>that</u> the notice required in item
(2) of subsection (e), the assigned independent review

HB0224 Enrolled - 38 - LRB097 05693 RPM 45756 b

organization shall provide written confirmation of the decision to the <u>Director, the</u> health carrier, the covered person, and, if applicable, the covered person's authorized representative including the information set forth in subsection (j) of Section 35 of this Act as applicable.

6 (i) An expedited external review may not be provided for 7 retrospective adverse or final adverse determinations.

8 <u>(j) The assignment by the Director of an approved</u> 9 <u>independent review organization to conduct an external review</u> 10 <u>in accordance with this Section shall be done on a random basis</u> 11 <u>among those independent review organizations approved by the</u> 12 <u>Director pursuant to this Act.</u>

13 (Source: P.A. 96-857, eff. 7-1-10; revised 9-16-10.)

14 (215 ILCS 180/42 new)

15 <u>Sec. 42. External review of experimental or</u>
 16 <u>investigational treatment adverse determinations.</u>

(a) Within 4 months after the date of receipt of a notice 17 18 of an adverse determination or final adverse determination that involves a denial of coverage based on a determination that the 19 20 health care service or treatment recommended or requested is experimental or investigational, a covered person or the 21 22 covered person's authorized representative may file a request 23 for an external review with the Director. 24 (b) The following provisions apply to cases concerning

25 <u>expedited external reviews:</u>

HB0224 Enrolled - 39 - LRB097 05693 RPM 45756 b

1(1) A covered person or the covered person's author2representative may make an oral request for an experimentation or3external review of the adverse determination or	
	edited
3 external review of the adverse determination or	
	final
4 adverse determination pursuant to subsection (a) of	<u>this</u>
5 <u>Section if the covered person's treating phys</u>	sician
6 <u>certifies</u> , in writing, that the recommended or requ	lested
7 <u>health care service or treatment that is the subject of the sub</u>	of the
8 <u>request would be significantly less effective is</u>	<u>f not</u>
9 promptly initiated.	
10 (2) Upon receipt of a request for an expedited ext	ternal
11 review, the Director shall immediately notify the h	nealth
12 <u>carrier</u> .	
13 (3) The following provisions apply concerning not:	ice:
14 (A) Upon notice of the request for an expe	edited
15 external review, the health carrier shall immed	iately
16 determine whether the request meets the reviewak	<u>pility</u>
17 requirements of subsection (d) of this Section	. The
18 health carrier shall immediately notify the Dir	rector
19 and the covered person and, if applicable, the co	overed
20 person's authorized representative of its eligib	<u>pility</u>
21 <u>determination.</u>	
22 (B) The Director may specify the form fo	r the
23 health carrier's notice of initial determination	under
24 subdivision (A) of this item (3) and any suppo	orting
25 <u>information to be included in the notice.</u>	

HB0224 Enrolled - 40 - LRB097 05693 RPM 45756 b

1	subdivision (A) of this item (3) shall include a
2	statement informing the covered person and, if
3	applicable, the covered person's authorized
4	representative that a health carrier's initial
5	determination that the external review request is
6	ineligible for review may be appealed to the Director.
7	(4) The following provisions apply concerning the
8	Director's determination:
9	(A) The Director may determine that a request is
10	eligible for external review under subsection (d) of
11	this Section notwithstanding a health carrier's
12	initial determination that the request is ineligible
13	and require that it be referred for external review.
14	(B) In making a determination under subdivision
15	(A) of this item (4), the Director's decision shall be
16	made in accordance with the terms of the covered
17	person's health benefit plan, unless such terms are
18	inconsistent with applicable law, and shall be subject
19	to all applicable provisions of this Act.
20	(5) Upon receipt of the notice that the expedited
21	external review request meets the reviewability
22	requirements of subsection (d) of this Section, the
23	Director shall immediately assign an independent review
24	organization to review the expedited request from the list
25	of approved independent review organizations compiled and
26	maintained by the Director and notify the health carrier of

HB0224 Enrolled - 41 - LRB097 05693 RPM 45756 b

1	the name of the assigned independent review organization.
2	(6) At the time the health carrier receives the notice
3	of the assigned independent review organization, the
4	health carrier or its designee utilization review
5	organization shall provide or transmit all necessary
6	documents and information considered in making the adverse
7	determination or final adverse determination to the
8	assigned independent review organization electronically or
9	by telephone or facsimile or any other available
10	expeditious method.
11	(c) Except for a request for an expedited external review
12	made pursuant to subsection (b) of this Section, within one
13	business day after the date of receipt of a request for
14	external review, the Director shall send a copy of the request
15	to the health carrier.
16	(d) Within 5 business days following the date of receipt of
17	the external review request, the health carrier shall complete
18	a preliminary review of the request to determine whether:
19	(1) the individual is or was a covered person in the
20	health benefit plan at the time the health care service was
21	recommended or requested or, in the case of a retrospective
22	review, at the time the health care service was provided;
23	(2) the recommended or requested health care service or
24	treatment that is the subject of the adverse determination
25	or final adverse determination is a covered benefit under
26	the covered person's health benefit plan except for the

HB0224 Enrolled - 42 - LRB097 05693 RPM 45756 b

1	health carrier's determination that the service or
2	treatment is experimental or investigational for a
3	particular medical condition and is not explicitly listed
4	as an excluded benefit under the covered person's health
5	benefit plan with the health carrier;
6	(3) the covered person's health care provider has
7	certified that one of the following situations is
8	applicable:
9	(A) standard health care services or treatments
10	have not been effective in improving the condition of
11	the covered person;
12	(B) standard health care services or treatments
13	are not medically appropriate for the covered person;
14	or
15	(C) there is no available standard health care
16	service or treatment covered by the health carrier that
17	is more beneficial than the recommended or requested
18	health care service or treatment;
19	(4) the covered person's health care provider:
20	(A) has recommended a health care service or
21	treatment that the physician certifies, in writing, is
22	likely to be more beneficial to the covered person, in
23	the physician's opinion, than any available standard
24	health care services or treatments; or
25	(B) who is a licensed, board certified or board
26	eligible physician qualified to practice in the area of

HB0224 Enrolled - 43 - LRB097 05693 RPM 45756 b

1	medicine appropriate to treat the covered person's
2	condition, has certified in writing that
3	scientifically valid studies using accepted protocols
4	demonstrate that the health care service or treatment
5	requested by the covered person that is the subject of
6	the adverse determination or final adverse
7	determination is likely to be more beneficial to the
8	covered person than any available standard health care
9	services or treatments;
10	(5) the covered person has exhausted the health
11	carrier's internal appeal process, unless the covered
12	person is not required to exhaust the health carrier's
13	internal appeal process pursuant to Section 30 of this Act;
14	and
15	(6) the covered person has provided all the information
16	and forms required to process an external review, as
17	specified in this Act.
18	(e) The following provisions apply concerning requests:
19	(1) Within one business day after completion of the
20	preliminary review, the health carrier shall notify the
21	Director and covered person and, if applicable, the covered
22	person's authorized representative in writing whether the
23	request is complete and eligible for external review.
24	(2) If the request:
25	(A) is not complete, then the health carrier shall
26	inform the Director and the covered person and, if

HB0224 Enrolled - 44 - LRB097 05693 RPM 45756 b

1	applicable, the covered person's authorized
2	representative in writing and include in the notice
3	what information or materials are required by this Act
4	to make the request complete; or
5	(B) is not eligible for external review, then the
6	health carrier shall inform the Director and the
7	covered person and, if applicable, the covered
8	person's authorized representative in writing and
9	include in the notice the reasons for its
10	ineligibility.
11	(3) The Department may specify the form for the health
12	carrier's notice of initial determination under this
13	subsection (e) and any supporting information to be
14	included in the notice.
15	(4) The notice of initial determination of
16	ineligibility shall include a statement informing the
17	covered person and, if applicable, the covered person's
18	authorized representative that a health carrier's initial
19	determination that the external review request is
20	ineligible for review may be appealed to the Director by
21	filing a complaint with the Director.
22	(5) Notwithstanding a health carrier's initial
23	determination that the request is ineligible for external
24	review, the Director may determine that a request is
25	eligible for external review and require that it be
26	referred for external review. In making such

HB0224 Enrolled - 45 - LRB097 05693 RPM 45756 b

determination, the Director's decision shall be in 1 2 accordance with the terms of the covered person's health 3 benefit plan, unless such terms are inconsistent with applicable law, and shall be subject to all applicable 4 5 provisions of this Act. (f) Whenever a request for external review is determined 6 7 eligible for external review, the health carrier shall notify 8 the Director and the covered person and, if applicable, the 9 covered person's authorized representative. (g) Whenever the Director receives notice that a request is 10 11 eligible for external review following the preliminary review 12 conducted pursuant to this Section, within one business day after the date of receipt of the notice, the Director shall: 13 14 (1) assign an independent review organization from the 15 list of approved independent review organizations compiled 16 and maintained by the Director pursuant to this Act and notify the health carrier of the name of the assigned 17 18 independent review organization; and 19 (2) notify in writing the covered person and, if 20 applicable, the covered person's authorized representative 21 of the request's eligibility and acceptance for external 22 review and the name of the independent review organization. 23 The Director shall include in the notice provided to the 24 covered person and, if applicable, the covered person's 25 authorized representative a statement that the covered person 26 or the covered person's authorized representative may, within 5

HB0224 Enrolled - 46 - LRB097 05693 RPM 45756 b

business days following the date of receipt of the notice 1 2 provided pursuant to item (2) of this subsection (q), submit in 3 writing to the assigned independent review organization additional information that the independent review 4 organization shall consider when conducting the external 5 review. The independent review organization is not required to, 6 but may, accept and consider additional information submitted 7 8 after 5 business days. 9 (h) The following provisions apply concerning assignments 10 and clinical reviews: 11 (1) Within one business day after the receipt of the 12 notice of assignment to conduct the external review pursuant to subsection (q) of this Section, the assigned 13 14 independent review organization shall select one or more clinical reviewers, as it determines is appropriate, 15 16 pursuant to item (2) of this subsection (h) to conduct the 17 external review. (2) The provisions of this item (2) apply concerning 18 the selection of reviewers: 19 20 (A) In selecting clinical reviewers pursuant to 21 item (1) of this subsection (h), the assigned independent review organization shall select 22 23 physicians or other health care professionals who meet 24 the minimum qualifications described in Section 55 of 25 this Act and, through clinical experience in the past 3 26 years, are experts in the treatment of the covered

1	person's condition and knowledgeable about the
2	recommended or requested health care service or
3	treatment.
4	(B) Neither the covered person, the covered
5	person's authorized representative, if applicable, nor
6	the health carrier shall choose or control the choice
7	of the physicians or other health care professionals to
8	be selected to conduct the external review.
9	(3) In accordance with subsection (1) of this Section,
10	each clinical reviewer shall provide a written opinion to
11	the assigned independent review organization on whether
12	the recommended or requested health care service or
13	treatment should be covered.
14	(4) In reaching an opinion, clinical reviewers are not
15	bound by any decisions or conclusions reached during the
16	health carrier's utilization review process or the health
17	carrier's internal appeal process.
18	(i) Within 5 business days after the date of receipt of the
19	notice provided pursuant to subsection (g) of this Section, the
20	health carrier or its designee utilization review organization
21	shall provide to the assigned independent review organization
22	the documents and any information considered in making the
23	adverse determination or final adverse determination; in such
24	cases, the following provisions shall apply:
25	(1) Except as provided in item (2) of this subsection
26	(i), failure by the health carrier or its utilization

HB0224 Enrolled - 48 - LRB097 05693 RPM 45756 b

1 review organization to provide the documents and 2 information within the specified time frame shall not delay 3 the conduct of the external review.

4 <u>(2) If the health carrier or its utilization review</u> 5 <u>organization fails to provide the documents and</u> 6 <u>information within the specified time frame, the assigned</u> 7 <u>independent review organization may terminate the external</u> 8 <u>review and make a decision to reverse the adverse</u> 9 <u>determination or final adverse determination.</u>

10 (3) Immediately upon making the decision to terminate 11 the external review and make a decision to reverse the 12 adverse determination or final adverse determination under item (2) of this subsection (i), the independent review 13 14 organization shall notify the Director, the health carrier, the covered person, and, if applicable, the 15 16 covered person's authorized representative of its decision to reverse the adverse determination. 17

18 (j) Upon receipt of the information from the health carrier 19 or its utilization review organization, each clinical reviewer 20 selected pursuant to subsection (h) of this Section shall 21 review all of the information and documents and any other 22 information submitted in writing to the independent review 23 organization by the covered person and the covered person's 24 authorized representative.

(k) Upon receipt of any information submitted by the
 covered person or the covered person's authorized

	HB0224 Enrolled - 49 - LRB097 05693 RPM 45756 b
1	representative, the independent review organization shall
2	forward the information to the health carrier within one
3	business day. In such cases, the following provisions shall
4	apply:
5	(1) Upon receipt of the information, if any, the health
6	carrier may reconsider its adverse determination or final
7	adverse determination that is the subject of the external
8	review.
9	(2) Reconsideration by the health carrier of its
10	adverse determination or final adverse determination shall
11	not delay or terminate the external review.
12	(3) The external review may be terminated only if the
13	health carrier decides, upon completion of its
14	reconsideration, to reverse its adverse determination or
15	final adverse determination and provide coverage or
16	payment for the health care service that is the subject of
17	the adverse determination or final adverse determination.
18	In such cases, the following provisions shall apply:
19	(A) Immediately upon making its decision to
20	reverse its adverse determination or final adverse
21	determination, the health carrier shall notify the
22	Director, the covered person and, if applicable, the
23	covered person's authorized representative, and the
24	assigned independent review organization in writing of
25	its decision.
26	(B) Upon notice from the health carrier that the

HB0224 Enrolled - 50 - LRB097 05693 RPM 45756 b

health carrier has made a decision to reverse its 1 2 adverse determination or final adverse determination, 3 the assigned independent review organization shall terminate the external review. 4 5 (1) The following provisions apply concerning clinical 6 review opinions: 7 (1) Except as provided in item (3) of this subsection 8 (1), within 20 days after being selected in accordance with 9 subsection (h) of this Section to conduct the external 10 review, each clinical reviewer shall provide an opinion to 11 the assigned independent review organization on whether 12 the recommended or requested health care service or 13 treatment should be covered. 14 (2) Except for an opinion provided pursuant to item (3) of this subsection (1), each clinical reviewer's opinion 15 16 shall be in writing and include the following information: (A) a description of the covered person's medical 17 18 condition; 19 (B) a description of the indicators relevant to 20 determining whether there is sufficient evidence to 21 demonstrate that the recommended or requested health 22 care service or treatment is more likely than not to be 23 beneficial to the covered person than any available 24 standard health care services or treatments and the 25 adverse risks of the recommended or requested health 26 care service or treatment would not be substantially

HB0224 Enrolled - 51 - LRB097 05693 RPM 45756 b

1	increased over those of available standard health care
2	services or treatments;
3	(C) a description and analysis of any medical or
4	scientific evidence considered in reaching the
5	opinion;
6	(D) a description and analysis of any
7	evidence-based standard; and
8	(E) information on whether the reviewer's
9	rationale for the opinion is based on clause (A) or (B)
10	of item (5) of subsection (m) of this Section.
11	(3) The provisions of this item (3) apply concerning
12	the timing of opinions:
13	(A) For an expedited external review, each
14	clinical reviewer shall provide an opinion orally or in
15	writing to the assigned independent review
16	organization as expeditiously as the covered person's
17	medical condition or circumstances requires, but in no
18	event more than 5 calendar days after being selected in
19	accordance with subsection (h) of this Section.
20	(B) If the opinion provided pursuant to
21	subdivision (A) of this item (3) was not in writing,
22	then within 48 hours following the date the opinion was
23	provided, the clinical reviewer shall provide written
24	confirmation of the opinion to the assigned
25	independent review organization and include the
26	information required under item (2) of this subsection

## HB0224 Enrolled - 52 - LRB097 05693 RPM 45756 b

1	<u>(1).</u>
2	(m) In addition to the documents and information provided
3	by the health carrier or its utilization review organization
4	and the covered person and the covered person's authorized
5	representative, if any, each clinical reviewer selected
6	pursuant to subsection (h) of this Section, to the extent the
7	information or documents are available and the clinical
8	reviewer considers appropriate, shall consider the following
9	in reaching a decision:
10	(1) the covered person's pertinent medical records;
11	(2) the covered person's health care provider's
12	recommendation;
13	(3) consulting reports from appropriate health care
14	providers and other documents submitted by the health
15	carrier or its designee utilization review organization,
16	the covered person, the covered person's authorized
17	representative, or the covered person's treating physician
18	or health care professional;
19	(4) the terms of coverage under the covered person's
20	health benefit plan with the health carrier to ensure that,
21	but for the health carrier's determination that the
22	recommended or requested health care service or treatment
23	that is the subject of the opinion is experimental or
24	investigational, the reviewer's opinion is not contrary to
25	the terms of coverage under the covered person's health
26	benefit plan with the health carrier; and

HB0224 Enrolled - 53 - LRB097 05693 RPM 45756 b

1	(5) whether (A) the recommended or requested health
2	care service or treatment has been approved by the federal
3	
4	condition or (B) medical or scientific evidence or
5	evidence-based standards demonstrate that the expected
6	benefits of the recommended or requested health care
7	service or treatment is more likely than not to be
8	beneficial to the covered person than any available
9	standard health care service or treatment and the adverse
10	risks of the recommended or requested health care service
11	or treatment would not be substantially increased over
12	those of available standard health care services or
13	treatments.
14	(n) The following provisions apply concerning decisions,
15	notices, and recommendations:
16	(1) The provisions of this item (1) apply concerning
17	decisions and notices:
18	(A) Except as provided in subdivision (B) of this
18 19	(A) Except as provided in subdivision (B) of this item (1), within 20 days after the date it receives the
19	item (1), within 20 days after the date it receives the
19 20	item (1), within 20 days after the date it receives the opinion of each clinical reviewer, the assigned
19 20 21	item (1), within 20 days after the date it receives the opinion of each clinical reviewer, the assigned independent review organization, in accordance with
19 20 21 22	item (1), within 20 days after the date it receives the opinion of each clinical reviewer, the assigned independent review organization, in accordance with item (2) of this subsection (n), shall make a decision
19 20 21 22 23	item (1), within 20 days after the date it receives the opinion of each clinical reviewer, the assigned independent review organization, in accordance with item (2) of this subsection (n), shall make a decision and provide written notice of the decision to the

1	(B) For an expedited external review, within 48
2	hours after the date it receives the opinion of each
3	clinical reviewer, the assigned independent review
4	organization, in accordance with item (2) of this
5	subsection (n), shall make a decision and provide
6	notice of the decision orally or in writing to the
7	Director, the health carrier, the covered person, and
8	the covered person's authorized representative, if
9	applicable. If such notice is not in writing, within 48
10	hours after the date of providing that notice, the
11	assigned independent review organization shall provide
12	written confirmation of the decision to the Director,
13	the health carrier, the covered person, and the covered
14	person's authorized representative, if applicable.
15	(2) The provisions of this item (2) apply concerning
16	recommendations:
17	(A) If a majority of the clinical reviewers
18	recommend that the recommended or requested health
19	care service or treatment should be covered, then the

20 independent review organization shall make a decision 21 to reverse the health carrier's adverse determination 22 or final adverse determination.

23 (B) If a majority of the clinical reviewers 24 recommend that the recommended or requested health 25 care service or treatment should not be covered, the 26 independent review organization shall make a decision

1	to uphold the health carrier's adverse determination
2	or final adverse determination.
3	(C) The provisions of this subdivision (C) apply to
4	cases in which the clinical reviewers are evenly split:
5	(i) If the clinical reviewers are evenly split
6	as to whether the recommended or requested health
7	care service or treatment should be covered, then
8	the independent review organization shall obtain
9	the opinion of an additional clinical reviewer in
10	order for the independent review organization to
11	make a decision based on the opinions of a majority
12	of the clinical reviewers pursuant to subdivision
13	(A) or (B) of this item (2).
14	(ii) The additional clinical reviewer selected
15	under clause (i) of this subdivision (C) shall use
16	the same information to reach an opinion as the
17	clinical reviewers who have already submitted
18	their opinions.
19	(iii) The selection of the additional clinical
20	reviewer under this subdivision (C) shall not
21	extend the time within which the assigned
22	independent review organization is required to
23	make a decision based on the opinions of the
24	clinical reviewers.
25	(o) The independent review organization shall include in
26	the notice provided pursuant to subsection (n) of this Section:

1	(1) a general description of the reason for the request
2	for external review;
3	(2) the written opinion of each clinical reviewer,
4	including the recommendation of each clinical reviewer as
5	to whether the recommended or requested health care service
6	or treatment should be covered and the rationale for the
7	reviewer's recommendation;
8	(3) the date the independent review organization
9	received the assignment from the Director to conduct the
10	external review;
11	(4) the time period during which the external review
12	was conducted;
13	(5) the date of its decision;
14	(6) the principal reason or reasons for its decision;
15	and
16	(7) the rationale for its decision.
17	(p) Upon receipt of a notice of a decision reversing the
18	adverse determination or final adverse determination, the
19	health carrier shall immediately approve the coverage that was
20	the subject of the adverse determination or final adverse
21	determination.
22	(q) The assignment by the Director of an approved
23	independent review organization to conduct an external review
24	in accordance with this Section shall be done on a random basis
25	among those independent review organizations approved by the
26	Director pursuant to this Act.

```
1
```

```
(215 ILCS 180/55)
```

Sec. 55. Minimum qualifications for independent review
 organizations.

4 (a) To be approved to conduct external reviews, an 5 independent review organization shall have and maintain 6 written policies and procedures that govern all aspects of both 7 the standard external review process and the expedited external 8 review process set forth in this Act that include, at a 9 minimum:

10

(1) a quality assurance mechanism that ensures that:

11 (A) external reviews are conducted within the 12 specified timeframes and required notices are provided 13 in a timely manner;

(B) selection of qualified and impartial clinical
reviewers to conduct external reviews on behalf of the
independent review organization and suitable matching
of reviewers to specific cases and that the independent
review organization employs or contracts with an
adequate number of clinical reviewers to meet this
objective;

21 (C) for adverse determinations involving 22 investigational treatments, experimental or in 23 assigning clinical reviewers, the independent review 24 organization selects physicians or other health care 25 professionals who, through clinical experience in the 1 past 3 years, are experts in the treatment of the 2 covered person's condition and knowledgeable about the 3 recommended or requested health care service or 4 treatment;

5 (D) the health carrier, the covered person, and the 6 covered person's authorized representative shall not 7 choose or control the choice of the physicians or other 8 health care professionals to be selected to conduct the 9 external review;

(E) confidentiality of medical and treatment
 records and clinical review criteria; and

12 (F) any person employed by or under contract with 13 the independent review organization adheres to the 14 requirements of this Act;

(2) a toll-free telephone service operating on a
24-hour-day, 7-day-a-week basis that accepts, receives,
and records information related to external reviews and
provides appropriate instructions; and

19 (3) an agreement to maintain and provide to the20 Director the information set out in Section 70 of this Act.

(b) All clinical reviewers assigned by an independent review organization to conduct external reviews shall be physicians or other appropriate health care providers who meet the following minimum qualifications:

(1) be an expert in the treatment of the covered
 person's medical condition that is the subject of the

HB0224 Enrolled

1 external review;

2 (2) be knowledgeable about the recommended health care 3 service or treatment through recent or current actual 4 clinical experience treating patients with the same or 5 similar medical condition of the covered person;

6 (3) hold a non-restricted license in a state of the 7 United States and, for physicians, a current certification 8 by a recognized American medical specialty board in the 9 area or areas appropriate to the subject of the external 10 review; and

11 (4) have no history of disciplinary actions or 12 including loss of staff privileges sanctions, or participation restrictions, that have been taken or are 13 14 pending by any hospital, governmental agency or unit, or 15 regulatory body that raise a substantial question as to the 16 clinical reviewer's physical, mental, or professional 17 competence or moral character.

(c) In addition to the requirements set forth in subsection
(a), an independent review organization may not own or control,
be a subsidiary of, or in any way be owned, or controlled by,
or exercise control with a health benefit plan, a national,
State, or local trade association of health benefit plans, or a
national, State, or local trade association of health care
providers.

(d) Conflicts of interest prohibited. In addition to the
 requirements set forth in subsections (a), (b), and (c) of this

HB0224 Enrolled - 60 - LRB097 05693 RPM 45756 b

Section, to be approved pursuant to this Act to conduct an 1 2 external review of a specified case, neither the independent review organization selected to conduct the external review nor 3 any clinical reviewer assigned by the independent organization 4 5 to conduct the external review may have a material professional, familial or financial conflict of interest with 6 7 any of the following:

8 (1) the health carrier that is the subject of the
9 external review;

10 (2) the covered person whose treatment is the subject 11 of the external review or the covered person's authorized 12 representative;

13 (3) any officer, director or management employee of the
14 health carrier that is the subject of the external review;

15 (4) the health care provider, the health care 16 provider's medical group or independent practice 17 association recommending the health care service or treatment that is the subject of the external review; 18

19 (5) the facility at which the recommended health care20 service or treatment would be provided; or

(6) the developer or manufacturer of the principal drug, device, procedure, or other therapy being recommended for the covered person whose treatment is the subject of the external review.

(e) An independent review organization that is accreditedby a nationally recognized private accrediting entity that has

independent review accreditation standards that the Director has determined are equivalent to or exceed the minimum qualifications of this Section shall be presumed to be in compliance with this Section and shall be eligible for approval under this Act.

6 (f) An independent review organization shall be unbiased. 7 An independent review organization shall establish and 8 maintain written procedures to ensure that it is unbiased in 9 addition to any other procedures required under this Section.

10 (g) Nothing in this Act precludes or shall be interpreted 11 to preclude a health carrier from contracting with approved 12 independent review organizations to conduct external reviews 13 assigned to it from such health carrier.

14 (Source: P.A. 96-857, eff. 7-1-10.)

15 (215 ILCS 180/65)

16 Sec. 65. External review reporting requirements.

(a) Each health carrier shall maintain written records in
the aggregate, by state, and for each type of health benefit
plan offered by the health carrier on all requests for external
review that the health carrier received notice from the
<u>Director</u> for each calendar year and submit a report to the
Director in the format specified by the Director by March 1 of
each year.

24 (a-5) An independent review organization assigned pursuant
 25 to this Act to conduct an external review shall maintain

HB0224 Enrolled - 62 - LRB097 05693 RPM 45756 b

1 written records in the aggregate by state and by health carrier 2 on all requests for external review for which it conducted an 3 external review during a calendar year and submit a report in the format specified by the Director by March 1 of each year. 4 5 (a-10) The report required by subsection (a-5) shall include in the aggregate by state, and for each health carrier: 6 7 (1) the total number of requests for external review; 8 (2) the number of requests for external review resolved 9 and, of those resolved, the number resolved upholding the 10 adverse determination or final adverse determination and 11 the number resolved reversing the adverse determination or 12 final adverse determination; (3) the average length of time for resolution; 13 14 (4) a summary of the types of coverages or cases for 15 which an external review was sought, as provided in the 16 format required by the Director; (5) the number of external reviews that were terminated 17 18 as the result of a reconsideration by the health carrier of 19 its adverse determination or final adverse determination 20 after the receipt of additional information from the 21 covered person or the covered person's authorized 22 representative; and 23 (6) any other information the Director may request or 24 require. 25 (a-15) The independent review organization shall retain 26 the written records required pursuant to this Section for at

HB0224 Enrolled

## - 63 - LRB097 05693 RPM 45756 b

1 least 3 years.

2 (b) The report required under subsection (a) of this 3 Section shall include in the aggregate, by state, and by type of health benefit plan: 4 5 (1) the total number of requests for external review; 6 (2) the total number of requests for expedited external 7 review; 8 (3) the total number of requests for external review 9 denied: number of requests for external review 10 (4)the 11 resolved, including: 12 (A) the number of requests for external review 13 resolved upholding the adverse determination or final adverse determination: 14 (B) the number of requests for external review 15 16 resolved reversing the adverse determination or final 17 adverse determination; (C) the number of requests for expedited external 18 review resolved upholding the adverse determination or 19 20 final adverse determination; and 21 (D) the number of requests for expedited external 22 review resolved reversing the adverse determination or 23 final adverse determination: (5) the average length of time for resolution for an 24 25 external review; 26 (6) the average length of time for resolution for an

1 expedited external review;

(7) a summary of the types of coverages or cases for

3

2

which an external review was sought, as specified below:

(A) denial of care or treatment (dissatisfaction
regarding prospective non-authorization of a request
for care or treatment recommended by a provider
excluding diagnostic procedures and referral requests;
partial approvals and care terminations are also
considered to be denials);

10 (B) denial of diagnostic procedure 11 (dissatisfaction regarding prospective 12 non-authorization of a request for a diagnostic 13 procedure recommended by a provider; partial approvals 14 are also considered to be denials);

15 (C) denial of referral request (dissatisfaction 16 regarding non-authorization of a request for a 17 referral to another provider recommended by a PCP);

(D) claims and utilization review (dissatisfaction 18 19 regarding the concurrent or retrospective evaluation 20 of the coverage, medical necessity, efficiency or appropriateness of health care services or treatment 21 22 plans; prospective "Denials of care or treatment", 23 "Denials of diagnostic procedures" and "Denials of referral requests" should not be classified in this 24 25 category, but the appropriate one above);

26 (8) the number of external reviews that were terminated

HB0224 Enrolled - 65 - LRB097 05693 RPM 45756 b

as the result of a reconsideration by the health carrier of its adverse determination or final adverse determination after the receipt of additional information from the covered person or the covered person's authorized persontative; and

6 (9) any other information the Director may request or 7 require.

8 (Source: P.A. 96-857, eff. 7-1-10.)

- 9 (215 ILCS 180/75)
- 10

Sec. 75. Disclosure requirements.

(a) Each health carrier shall include a description of the external review procedures in, or attached to, the policy, certificate, membership booklet, and outline of coverage or other evidence of coverage it provides to covered persons.

(b) The description required under subsection (a) of this 15 Section shall include a statement that informs the covered 16 person of the right of the covered person to file a request for 17 an external review of an adverse determination or final adverse 18 19 determination with the Director health carrier. The statement shall explain that external review is available when the 20 21 adverse determination or final adverse determination involves 22 an issue of medical necessity, appropriateness, health care 23 setting, level of care, or effectiveness. The statement shall 24 include the toll-free telephone number and address of the 25 Office of Consumer Health Insurance within the Department of

HB0224 Enrolled	- 66 -	LRB097 0.	5693 RPM	45756 b
Insurance.				
(Source: P.A. 96-857, eff.	7-1-10.)			
(215 ILCS 180/80 new)				
Sec. 80. Administration	and enford	ement.		
<u>(a) The Director of Ins</u>	surance may	adopt rul	es neces	sary to
implement the Department's	responsibil	lities unde	er this A	Act.
<u>(b) The Director is au</u>	thorized t	o make use	e of any	of the
powers established under th	e Illinois	Insurance	Code to	enforce
the laws of this State. Th	is include	s but is :	not limi	ted to,
the Director's administrat:	ive authori	ty to inv	estigate	, issue
subpoenas, conduct deposit	tions and	hearings,	issue	orders,
including, without limitat:	ion, orders	pursuant	to Arti	cle XII
1/2 and Section 401.1 of	the Illin	ois Insur	ance Co	de, and
impose penalties.				
				<b>-</b>
	<pre>Insurance. (Source: P.A. 96-857, eff.  (215 ILCS 180/80 new)     Sec. 80. Administration     (a) The Director of Ins     implement the Department's         (b) The Director is au     powers established under the     the laws of this State. The     the Director's administrat:     subpoenas, conduct deposition     including, without limitat:     1/2 and Section 401.1 of     impose penalties.</pre>	<pre>Insurance. (Source: P.A. 96-857, eff. 7-1-10.) (215 ILCS 180/80 new) Sec. 80. Administration and enform (a) The Director of Insurance may implement the Department's responsibil (b) The Director is authorized to powers established under the Illinois the laws of this State. This include the Director's administrative authori subpoenas, conduct depositions and including, without limitation, orders 1/2 and Section 401.1 of the Illin impose penalties.</pre>	<pre>Insurance. (Source: P.A. 96-857, eff. 7-1-10.)  (215 ILCS 180/80 new) Sec. 80. Administration and enforcement. (a) The Director of Insurance may adopt rul implement the Department's responsibilities under (b) The Director is authorized to make use powers established under the Illinois Insurance the laws of this State. This includes but is the Director's administrative authority to inv subpoenas, conduct depositions and hearings, including, without limitation, orders pursuant 1/2 and Section 401.1 of the Illinois Insur impose penalties.</pre>	<pre>Insurance. (Source: P.A. 96-857, eff. 7-1-10.) (215 ILCS 180/80 new) <u>Sec. 80. Administration and enforcement.</u> (a) The Director of Insurance may adopt rules necess implement the Department's responsibilities under this A (b) The Director is authorized to make use of any powers established under the Illinois Insurance Code to the laws of this State. This includes but is not limit the Director's administrative authority to investigate subpoenas, conduct depositions and hearings, issue including, without limitation, orders pursuant to Artii 1/2 and Section 401.1 of the Illinois Insurance Code</pre>

Section 99. Effective date. This Act takes effect on July 16 1, 2011.